≥99% HPLCPre-filled pen

PT-141 (Bremelanotide)

Name: PT-141 (Bremelanotide)
Brand: Dripfy
Availability: InStock

What it is?

PT-141 is a melanocortin-pathway peptide studied for its role in central arousal and desire signalling. It is positioned to influence libido through CNS mechanisms, rather than relying solely on peripheral vascular modulation.

Dripfy Advantage

Receptor engagement: Targets melanocortin receptors implicated in sexual motivation and arousal signalling (CNS-focused pathway).
Neuro-signalling modulation: Associated with regulation of neural circuits linked to sexual response, supporting desire-related endpoints in controlled settings.
Non-vascular primary mechanism: Positioned as a central-acting approach, distinct from strategies that primarily target blood-flow dynamics.
Cross-sex applicability: Commonly framed for both male and female sexual wellness research endpoints, depending on protocol design and screening.

Clinical Applications & Therapeutic Potential

Libido and arousal endpoints: Potential support for improved desire and arousal-response markers in CNS-mediated sexual function protocols.
Sexual satisfaction outcomes: Potential improvement in sexual satisfaction–related endpoints in appropriately selected cohorts (context-dependent).
CNS-driven dysfunction frameworks: Positioned for cases where reduced libido is linked to neuro-signalling factors rather than purely mechanical drivers.
Male and female protocols: Often discussed for broad applicability, with outcomes dependent on baseline neuroendocrine context and protocol controls.

Composition & Formulation

Peptide Content: 10 mg PT-141 (Bremelanotide)
Vehicle: Proprietary pH-balanced buffer solution
Delivery System: Pre-filled, multi-dose, closed-system pen
Total Volume: 3 mL
Purity: ≥99% by HPLC/MS

€478

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

PT-141 (Bremelanotide)

Centrally acting melanocortin receptor agonist · Pre-filled pen

B· Moderate evidence

PT-141 (bremelanotide) is a centrally acting melanocortin receptor agonist. It engages melanocortin receptors — MC4R in particular — within brain circuits that govern sexual motivation and arousal, so its primary action is on desire signalling in the CNS rather than on peripheral blood flow. This central mechanism is what distinguishes it from vasodilator-type approaches to sexual function.

Studied use areas

Acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women — the indication for which bremelanotide (Vyleesi) is FDA-approved in the US (no UK or EU authorisation)
Central (brain-driven) sexual desire and arousal signalling
Sexual-wellness research in both women and men, depending on screening
As an approach distinct from blood-flow-focused erectile therapies

Safety & status

Not authorised in the UK or EU (no MHRA or EMA marketing authorisation); in the US it is a prescription-only medicine (Vyleesi), so any use requires a qualified prescriber
Commonly reported effects include nausea, flushing and headache; each dose causes a transient rise in blood pressure and a small fall in heart rate, and it is contraindicated in uncontrolled hypertension or known cardiovascular disease, so cardiovascular screening matters
Melanocortin activation can trigger focal darkening of skin or gums (hyperpigmentation) in some users
Not suitable for self-directed use; suitability and any regimen are decided case by case by the treating physician

⚕ Clinical note: This card is educational and is not medical advice, a diagnosis, or a recommendation to use any product. Bremelanotide is a US prescription medicine with no UK or EU marketing authorisation; it must be assessed, prescribed and monitored by a qualified physician; never self-source or self-administer it.

Evidence: Grade B — approved in the US (FDA, 2019) as bremelanotide (Vyleesi) for premenopausal HSDD, with supporting randomised controlled trials; not authorised in the UK or EU; benefit is real but modest and patient-selected. · References: FDA prescribing information for Vyleesi (bremelanotide injection); Peer-reviewed randomised controlled trials on bremelanotide for HSDD; Pharmacology reviews of centrally acting sexual-medicine agents